United Kingdom Gene Therapy Market Size, Share, and COVID-19 Impact Analysis, By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, and Non-Viral Methods), By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, and Neurological Disorders), and UK Gene Therapy Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Gene Therapy Market Forecasts to 2035

• The United Kingdom Gene Therapy Market Size Was Estimated at USD 354.6 Million in 2024
• The UK Gene Therapy Market Size is Expected to Grow at a CAGR of around 16.97% from 2025 to 2035
• The UK Gene Therapy Market Size is Expected to Reach USD 1987.8 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the UK Gene Therapy Market Size is anticipated to reach USD 1987.8 Million by 2035, growing at a CAGR of 16.97% from 2025 to 2035. The UK Gene Therapy Market is driven by robust healthcare infrastructure, rising investments in research operations, advanced regulatory frameworks, and the presence of leading biotechnology firms fostering innovation.

Market Overview

The UK Gene Therapy Market refers to a procedure that uses a gene to treat, prevent, or cure a disease or medical condition. Gene therapies often involve inserting new copies of a damaged gene or replacing a defective or missing gene in a patient's cells with a healthy version of that gene. Gene therapy has been used for hereditary genetic conditions, for example, haemophilia and sickle cell disease, and has also been used in the treatment of acquired conditions such as leukaemia. Gene therapy is changing the landscape of modern medicine by curing the genetic basis of disease, rather than only treating the symptoms of disease. The gene therapy market in the UK is expanding rapidly as a result of recent technological advances with CRISPR, the emergence of better gene editing tools, and advancements in delivery mechanisms. With increasing investment from public and private sectors, a favourable regulatory environment, and an increasing pipeline of possible therapies, the development and approval of especially innovative therapies is accelerating. The increasing incidence of patients affected by rare and inherited genetic disorders is also contributing to the market growth. As clinical trials become more common and successful, confidence among researchers, investors, and healthcare providers in the promise gene therapy holds is growing. Therapeutic options that prompt a permanent and long-lasting cure or significant quality of life improvements, especially in non-treatable conditions, are a hopeful prospect. The UK gene therapy sector has significant growth potential, owing to government support, clinical trial financing, and a focus on uncommon disorders. Collaboration between academia and industry promotes innovation, while advances in biotechnology and genomics create new prospects for faster, more impactful medication development and commercialisation. With continued advancements and increasing support, the UK gene therapy market is poised to play a leading role in shaping the future of genetic medicine.

Report Coverage

This research report categorizes the market for the UK gene therapy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom gene therapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom gene therapy market.

Driving Factors

The UK gene therapy market is experiencing significant growth, driven by the rising incidence of genetic disorders. This growing patient population highlights a strong demand for innovative treatments. Organisations like the NHS and Genomics England are advancing genetic screening and supporting therapy development. Technological progress in gene delivery systems, including viral vectors and nanoparticle technologies, is enhancing the safety and effectiveness of gene therapies. The UK government supports this innovation through biotech funding and R&D incentives. Major pharmaceutical companies are boosting investments. These investments have been fuelled by the UK government's supportive policies, such as tax breaks for research and development. These combined efforts position the UK as a leading hub for gene therapy development, fostering a dynamic and forward-looking market growth.

Restraining Factors

Gene therapy is faced with several challenges that limit its widespread usage. Patients don’t have equal access to treatment due to high treatment costs; the development and manufacturing steps can be complex, which drives the price. Safety is a key consideration. Patients may experience an immune reaction to the treatment, and existing therapies have not been studied for long-term adverse effects. Regulatory paths for gene therapies can be lengthy and vary from region to region, limiting the number of new therapies approved and available to patients. There are ethical issues, especially because germline editing is a part of the science behind gene therapies, and there remain discussions and disagreements between scientists, regulators, and the public about gene editing. These factors can hamper the UK gene therapy market during the forecast period.

Market Segmentation

The United Kingdom gene therapy market share is classified into technology and therapeutic areas.

• The viral vectors segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom gene therapy market is segmented by technology into viral vectors, CRISPR, gene editing, RNA therapy, and non-viral methods. Among these, the viral vectors segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. Viral vectors are praised for their extraordinary accuracy in delivering genetic material to their intended cells. They are essential for gene therapy because of their high transduction efficiency and capacity to incorporate into host genomes. Furthermore, the segment's dominance has been further cemented by the growing demand for tailored delivery systems and precision medicine. Important developments in vector engineering have improved their effectiveness and safety, allaying prior worries about insertional mutagenesis and immunological reactions. Because viral vectors are used to treat rare diseases, cancers, and genetic defects, this industry is expected to grow gradually.

• The oncology segment held the highest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom gene therapy market is segmented by therapeutic area into oncology, genetic disorders, infectious diseases, cardiovascular diseases, and neurological disorders. Among these, the oncology segment held the highest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The increasing incidence of cancer in the UK and the expanding use of gene treatments due to their superior precision in targeting particular cancer cells are the main causes of this dominance. With fewer side effects than chemotherapy and radiation, gene therapies are becoming a very popular substitute for conventional cancer treatments. Because of this benefit, gene therapy is a more alluring choice for both patients and medical professionals.
Furthermore, improvements in the treatment of haematologic malignancies including leukaemia and lymphoma, as well as the growing regulatory bodies' acceptance of gene therapies, have reinforced the market's expansion. Gene therapies are anticipated to increase their presence in oncology, especially for tumours for which there are few available treatments, as clinical trials continue to yield encouraging results.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom gene therapy market and a with comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Finite Resources
• Amgen
• Bluebird Bio
• Pfizer
• Regeneron Pharmaceuticals
• Roche
• GSK
• Sarepta Therapeutics
• Regenxbio
• Spark Therapeutic
• Celgene
• AstraZeneca
• Bristol Myers Squibb
• Novartis
• uniQure
• Others

Recent Developments:

• In August 2023, Pfizer and UniQure launched a strategic partnership to create gene medicines that target rare disorders. 

Key Target Audience

• Investors
• Market players
• End-users
• Government Authorities
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom gene therapy market based on the below-mentioned segments:

United Kingdom Gene Therapy Market, By Technology

• Viral Vectors
• CRISPR
• Gene Editing
• RNA Therapy
• Non-Viral Methods

United Kingdom Gene Therapy Market, By Therapeutic Area

• Oncology
• Genetic Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Disorders